Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

DEAR DR. ROACH: I take Zepbound. I accidentally left it out for a day, and I am worried that they will be dangerous if I use ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 0.32%) stock in ...

Dear C.D.: It seems to me that we humans have a protective mechanism that lets us forget just how sick we were when we had ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

NEW YORK (AP) — More U.S. children have died this flu season than at any time since the swine flu pandemic 15 years ago, according to a federal report released Friday. The 216 pediatric deaths ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Tim Friede has been bitten by snakes hundreds of times — often on purpose. Now scientists are studying his blood in hopes of ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.